Opaleye Management Inc. Makes New $563,000 Investment in OKYO Pharma Limited Sponsored ADR $OKYO

Opaleye Management Inc. purchased a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 375,204 shares of the company’s stock, valued at approximately $563,000.

A number of other large investors have also made changes to their positions in OKYO. Citadel Advisors LLC acquired a new stake in shares of OKYO Pharma in the third quarter valued at about $31,000. XTX Topco Ltd acquired a new position in OKYO Pharma during the fourth quarter worth about $36,000. Finally, Renaissance Technologies LLC increased its holdings in OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after buying an additional 96,800 shares in the last quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Trading Down 1.4%

Shares of NASDAQ OKYO opened at $1.43 on Friday. The company has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $1.59. OKYO Pharma Limited Sponsored ADR has a 12 month low of $1.34 and a 12 month high of $3.20.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on OKYO shares. HC Wainwright decreased their price target on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, OKYO Pharma has a consensus rating of “Hold” and a consensus target price of $5.67.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.